Skip to main content
540 search results for:

Sarilumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-04-2024 | Sarilumab | News

    Sarilumab

    Hepatotoxicity and infections
  2. 15-03-2024 | Erratum

    Correction to: Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry

  3. 06-01-2024 | Sarilumab | OriginalPaper

    Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry

    Interleukin-6 (IL-6) signaling is an important target in the inflammatory pathways of rheumatoid arthritis (RA). Sarilumab (SARI), which has followed tocilizumab (TCZ) onto the market as the second anti-IL-6 receptor monoclonal antibody drug …

  4. Open Access 13-11-2023 | Sarilumab | Erratum

    Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry

  5. Open Access 01-12-2023 | Sarilumab | OriginalPaper

    Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis

    Rheumatoid arthritis (RA) is a highly prevalent chronic systemic inflammatory disease. Clinically, RA is characterized by symmetrical peripheral polyarthritis with extraarticular manifestations [ 1 ]. The natural course of this disease may lead to …

  6. Open Access 01-12-2023 | Giant Cell Arteritis | OriginalPaper

    A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

    Giant cell arteritis (GCA) is the most common primary systemic vasculitis in people above 50 years of age and is more frequently reported in Caucasians and in females [ 1 , 2 ]. More than 3 million people are expected to be diagnosed with GCA by …

  7. 01-08-2022 | Sarilumab | News

    Sarilumab

    Neutropenia following off-label use: 2 case reports
  8. Open Access 22-06-2023 | Sarilumab | OriginalPaper

    Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry

    Sarilumab is a human monoclonal antibody that targets the interleukin-6-receptor (IL-6R). It has demonstrated efficacy in improving the signs and symptoms along with physical function in patients with rheumatoid arthritis (RA) who had an …

  9. 01-07-2021 | Sarilumab | OriginalPaper

    Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study

    The recommendations of the 2019 European League Against Rheumatism (EULAR) stated that the efficacies of anti-interleukin (IL)-6 receptor antibody (IL-6R; tocilizumab [TCZ] and sarilumab [SAR]), CTLA4-Ig (abatacept), and Janus kinase inhibitors …

  10. 01-01-2023 | Tocilizumab | News

    Sarilumab/tocilizumab

    Liver-injury: 4 case reports
  11. Open Access 01-02-2023 | Sarilumab | OriginalPaper

    Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison

    Targeted disease-modifying antirheumatic drugs (DMARDs), biologic or synthetic, are commonly prescribed for patients with rheumatoid arthritis (RA) who have a suboptimal response to conventional synthetic DMARDs alone [ 1 , 2 ]. As examples of the …

  12. Open Access 01-12-2020 | Adalimumab | OriginalPaper

    Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

    Patients with rheumatoid arthritis (RA) develop bone and cartilage damage in synovial joints as a result of chronic inflammation, which is mediated by pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α) …

  13. Open Access 01-12-2020 | Adalimumab | OriginalPaper

    High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab

    The understanding of the multifunctional role of interleukin-6 (IL-6) in biologic activities has expanded in the last decade [ 1 , 2 ]. Dysregulation of IL-6 has been implicated in the onset or development of several diseases, particularly …

  14. Open Access 01-12-2022 | Tocilizumab | OriginalPaper

    Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019

    At the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a new human pathogen. This unknown virus, which causes coronavirus disease 2019 (COVID-19), was named by the WHO on February 11, 2020. On March 11 …

  15. 01-01-2021 | Sarilumab | News

    Sarilumab

    Perforated duodenal ulcer: case report
  16. 01-12-2020 | Sarilumab | News

    Sarilumab

    Thrombocytopenia during an off-label use: case report
  17. 01-10-2020 | Sarilumab | News

    Sarilumab

    Cytomegalovirus colitis: case report
  18. Open Access 01-12-2021 | Adalimumab | OriginalPaper

    Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

    This article is published with digital features, including a video abstract to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.14512056 .

  19. Open Access 01-12-2021 | Sarilumab | Erratum

    Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

    In the original article published, there is an error in the video of the supplementary material. The correct supplementary material has been updated.

  20. 01-05-2024 | Sarilumab | News

    Alendronic-acid/sarilumab

    Medication-related osteonecrosis of the jaw, necrotising fasciitis and Bacteroides pyogenes infection

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.